SPAC Big Rock Partners Acquisition (BRPA) on Watch as Merger Partner NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI

March 26, 2021 9:48 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

SPAC Big Rock Partners Acquisition (NASDAQ: BRPA) on watch after merger partner NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 respiratory failure ( 04311697). The results for the primary endpoint of recovery from respiratory failure and the secondary endpoint of survival through day 60 are in the process of final review by the investigators of the multicenter clinical trial. A conference call will be held at 8:30am EDT on Monday, March 29th with attendance from corporate leadership and lead investigators.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, SPAC

Related Entities

Definitive Agreement, FDA, SPAC